Douglas Scientific, TATAA Biocenter Collaborate
News Jan 12, 2016
Douglas Scientific® has announced collaboration with TATAA Biocenter. Douglas Scientific has been working with TATAA since 2013, initially on software design for and performance testing of the IntelliQube platform, and now expands the partnership to include PCR services offered by TATAA Biocenter using the IntelliQube.
TATAA Biocenter maintains ISO 17025 accreditation and is supporting pharmaceutical, biotech and leading academic researchers with a full range of qualified nucleic acids analysis services. In 2013, TATAA Biocenter was presented the Frost & Sullivan Award for Customer Value Leadership as Best-in-Class Services for Analyzing Genetic Material.
“We are proud to partner with Douglas Scientific as a premier services provider in Europe. The new IntelliQube strengthens our already top-notch instrument park allowing us to offer certain services with unprecedented cost efficiency to our clients and helping them be more competitive”, says Mikael Kubista, CEO and founder of TATAA Biocenter.
Ross Higgins, a Business Development Executive with Douglas Scientific added, “Partnering with the upper echelon of organizations such as TATAA Biocenter has become a strategic imperative for us and it fits right into our mission of making the world a better place by advancing scientific discovery. We are excited to see the impactful research that will come out of projects at TATAA and our many other partners around the world who have adopted the IntelliQube for their qPCR-based research.”
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.